The 2025 DAVA Summit on Genitourinary Malignancies has come to a close. We extend our gratitude to all participants for their valuable insights, expertise, and engaging questions and answers. #DAVAGU

PSA screening in 2025 ⁦@DAVAOnc⁩ #Davagu

Nivolumab plus relatlimab continues to be explored in advanced ccRCC. Dr. Scott Tykodi @fredhutch reports FRACTION-RCC data showing limited activity post–IO therapy, but measurable ORR and PFS signals in IO-naïve patients, particularly with LAG-3 or PD-L1 expression. #DAVAGU

Starting Now: Optimizing Immunotherapy in RCC Moderated by: @MattZibelman @FoxChaseCancer #DAVAGU

ADT-associated cardiovascular toxicity shows significant racial disparities. @VivekNarayanMD reports that Black men starting ADT have higher MACE risk,& socioeconomic factors in the Social Vulnerability Index explain most of the difference,supporting integrated CV risk assessment

PSA screening provides a measurable mortality benefit with long-term follow-up. @WilliamOhMD emphasizes risk-stratified screening: earlier & more frequent testing for men with BRCA1/2, ATM, MMR mutations or Black ancestry, and discontinuation when life expectancy <10 yrs. #DAVAGU

Starting Now: Practical Considerations in Prostate Cancer Management Moderated by: @sartor_oliver #DAVAGU

Lineage plasticity in mCRPC involves JAK/STAT- and FGFR-activated transition states. @samirzaidi @YaleMed highlights preclinical data showing co-activation in NEPC-emergent models and introduces tinengotinib, a dual JAK/FGFR inhibitor under clinical evaluation. #DAVAGU

RIPTAC therapeutics represent a novel strategy for selective tumor killing in mCRPC. @DanielPetrylak @YaleMed presents early HLD-0915 data showing acceptable tolerability, PSA50/90 declines across dose levels, & objective responses including confirmed partial regressions. #DAVAGU

Epigenetic targeting is emerging as a strategy to overcome lineage plasticity in mCRPC. Dr. @mishabeltran @DanaFarber reviews EZH2 dysregulation and early data showing mevrometostat plus enzalutamide improves rPFS and modulates PRC2 activity in resistant disease. #DAVAGU

Starting Now: Novel Therapies and Targets in Prostate Cancer Moderated by: @EAntonarakis @UMNCancer #DAVAGU

Targeting the Epigenome as well as novel degraders in prostate cancer ⁦@DAVAOnc⁩ #Davagu

Amazing GU 2025 @DAVAOnc

Starting Now: Translational Studies in Bladder and Prostate Cancer Moderated by: @WilliamOhMD @YaleMed #DAVAGU

Dr. Saby George @Roswell Park reviews long-term outcomes from CheckMate 214, noting that IMAEs with nivolumab+ipilimumab may signal improved OS and extended treatment-free intervals, suggesting a potential predictive role in ccRCC management. #DAVAGU

Dr. @QianJanieQin @UTSWMedCenter presents early data using 89Zr-atezolizumab PET/CT to visualize heterogeneous PD-L1 expression in RCC, revealing inter- and intra-lesional variability that may refine IO response prediction and guide site-specific management. #DAVAGU

Starting Now: Biomarkers to Target Immunotherapy in RCC Moderated by: Dr. Scott Tykodi @fredhutch #DAVAGU

Day 5 begins at Bermuda GU 2025: Dr. Natalie Reizine @UofIllinois discusses using real-world data and causal inference to personalize treatment in advanced prostate cancer, highlighting OS and MACE variations between abiraterone and enzalutamide among frail patients. #DAVAGU

Starting Now: Leveraging Big Data in GU Malignancies Moderated by: @charlesryanmd @MSKCancerCenter #DAVAGU

Good morning from Bermuda! Join us for our final morning sessions where we dive deep into groundbreaking presentations and discussions on the latest advancements in genitourinary malignancies. Thank you for being part of the 2025 DAVA Bermuda GU Summit! #DAVAGU #Oncology